相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Cellular localization of P2X7 receptor mRNA in the rat brain
Yong Yu et al.
BRAIN RESEARCH (2008)
Inhibition of the ATP-gated P2X7 receptor promotes axonal growth and branching in cultured hippocampal neurons
Miguel Diaz-Hernandez et al.
JOURNAL OF CELL SCIENCE (2008)
Synaptic terminals from mice midbrain exhibit functional P2X7 receptor
P. Marin-Garcia et al.
NEUROSCIENCE (2008)
Huntington disease models and human neuropathology: similarities and differences
Jean Paul G. Vonsattel
ACTA NEUROPATHOLOGICA (2008)
Extracellular ATP mediates necrotic cell swelling in SN4741 dopaminergic neurons through P2X7 receptors
Dong-Jae Jun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Inhibitors of metabolism rescue cell death in Huntington's disease models
Hemant Varma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states
D. L. Donnelly-Roberts et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
P2x7-related modulation of pathological nociception in rats
S. McGaraughty et al.
NEUROSCIENCE (2007)
Kinetics of P2X7 receptor-operated single channels currents
T. Riedel et al.
BIOPHYSICAL JOURNAL (2007)
Revisiting safety of minocycline as neuroprotection in Huntington's disease
Norman Reynolds
MOVEMENT DISORDERS (2007)
Is the ubiquitin-proteasome system impaired in Huntington's disease?
Z. Ortega et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
Huntington's disease:: from huntingtin function and dysfunction to therapeutic strategies
M. Borrell-Pages et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
P2X7 receptor-dependent cell death is modulated during muirine T cell maturation and mediated by dual signalling pathways
Mitsutoshi Tsukimoto et al.
JOURNAL OF IMMUNOLOGY (2006)
Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle
Brigit E. Riley et al.
GENES & DEVELOPMENT (2006)
Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists
Derek W. Nelson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Staining ability and biocompatibility of brilliant blue G - Preclinical study of brilliant blue G as an adjunct for capsular staining
T Hisatomi et al.
ARCHIVES OF OPHTHALMOLOGY (2006)
Huntington's disease: seeing the pathogenic process through a genetic lens
James F. Gusella et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease
M Díaz-Hernández et al.
JOURNAL OF NEUROSCIENCE (2005)
Characterization of a functional P2X7-like receptor in cerebellar granule neurons from P2X7 knockout mice
J Sánchez-Nogueiro et al.
FEBS LETTERS (2005)
Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements
NA DiProspero et al.
JOURNAL OF NEUROCYTOLOGY (2004)
Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease
JM Canals et al.
JOURNAL OF NEUROSCIENCE (2004)
P2X7 receptor inhibition improves recovery after spinal cord injury
XH Wang et al.
NATURE MEDICINE (2004)
The promise of minocycline in neurology
VW Yong et al.
LANCET NEUROLOGY (2004)
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
M Arrasate et al.
NATURE (2004)
Huntingtin and the molecular pathogenesis of Huntington's disease - Fourth in molecular medicine review series
C Landles et al.
EMBO REPORTS (2004)
Minocycline is protective in a mouse model of Huntington's disease
S Hersch et al.
ANNALS OF NEUROLOGY (2003)
P2X7 receptors in rat brain:: Presence in synaptic terminals and granule cells
MT Miras-Portugal et al.
NEUROCHEMICAL RESEARCH (2003)
Huntington's disease: a synaptopathy?
JY Li et al.
TRENDS IN MOLECULAR MEDICINE (2003)
Minocycline and doxycycline are not beneficial in a model of Huntington's disease
DL Smith et al.
ANNALS OF NEUROLOGY (2003)
Targeting programmed cell death in neurodegenerative diseases
M Vila et al.
NATURE REVIEWS NEUROSCIENCE (2003)
Transcriptional abnormalities in Huntington disease
KL Sugars et al.
TRENDS IN GENETICS (2003)
Mechanisms of disease: Apoptosis and caspases in neurodegenerative diseases
RM Friedlander
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Response heterogeneity of human macrophages to ATP is associated with P2X7 receptor expression but not to polymorphisms in the P2RX7 promoter
CM Li et al.
FEBS LETTERS (2002)
Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders
CA Ross
NEURON (2002)
Extracellular ATP and P2X7 receptors in neurodegeneration
R Le Feuvre et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production
P Guidetti et al.
EXPERIMENTAL NEUROLOGY (2001)
Altered cytokine production in mice lacking P2X7 receptors
M Solle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
M Turmaine et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Energetics in the pathogenesis of neurodegenerative diseases
MF Beal
TRENDS IN NEUROSCIENCES (2000)
Brilliant Blue G selectively blocks ATP-gated rat P2X7 receptors
LH Jiang et al.
MOLECULAR PHARMACOLOGY (2000)
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
A Yamamoto et al.
CELL (2000)